What You Should Know:
– OMNY Health, a healthcare ecosystem provider for compliant real-world data insights at scale announced a significant expansion of its data network with the addition of more than 300 new clinical assessment measures.
– These disease-specific measures, derived from clinical severity indicators, surveys, and questionnaires, are poised to offer a more granular and nuanced real-world view of patient health, thereby enhancing the ability to monitor disease progression and the impact of treatments across numerous medical specialties.
– The newly incorporated measures include critical information such as the Crohn’s Disease Activity Index (CDAI) and the Harvey Bradshaw index for Gastroenterology, as well as the Asthma Control Test and COPD Assessment Test (CAT) for Respiratory conditions. This expansion allows for deeper research and insights into areas including respiratory, cardiovascular, autoimmune, gastroenterology, neurology, and oncology.
Broadening Horizons: From Dermatology Focus to Pan-Therapeutic Value
This development marks a strategic move for OMNY Health, building upon its successful data strategy initially demonstrated in dermatology. The company is now leveraging its capabilities to extract and curate data from both structured and unstructured sources within its extensive pool of electronic health records (EHRs) to serve a wider range of healthcare research needs.
“For some time, OMNY Health has been seen as a dermatology data network, but with our network growth, we are moving beyond that and demonstrating the value of our solutions to the broader healthcare community,” said Dr. Mitesh Rao, CEO and Co-Founder of OMNY Health. “By leveling up research and making more information available across multiple specialties, OMNY Health enables teams to fill information gaps, accelerate research timelines, and make meaningful improvements to patient care.”
Deeper Insights for Enhanced Research and Care
OMNY Health’s expanded curated measures offering provides comprehensive data on critical aspects of patient health, including:
- Longitudinal disease progression: Tracking flare-ups and treatment responses for chronic conditions such as asthma, COPD, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, lupus, epilepsy, and multiple sclerosis.
- Real-world evidence: Offering insights on risk factors, medication adherence, and patient outcomes for conditions like heart failure and hypertension.
- Post-surgical recovery: Enabling tracking of rehabilitation outcomes and treatment effectiveness across various conditions.
